Mirtazapine Mylan

Mirtazapine, the active ingredient in Mirtazapine Mylan, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mirtazapine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant indicated for major depressive disorder, acting on central neurotransmitter pathways.

Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Severe hypersensitivity reactions (rash, angioedema) - Suicidal thoughts or behavior, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents

Before prescribing Mirtazapine, clinicians should consider several safety aspects. - Hepatic function: assess liver enzymes in patients with hepatic impairment. - Suicidal risk: monitor for emergence or worsening of suicidal thoughts, particularly during the initial treatment period. - Elderly patients: use caution due to increased fall risk from sedation. - Discontinuation: avoid abrupt cessation; taper the dose to reduce withdrawal symptoms. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Central nervous system depressants (e.g., alcohol, benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Antihypertensives: additive hypotensive effect, monitor blood pressure.